Sean McCutcheon
Stock Analyst at Raymond James
(0.25)
# 4,197
Out of 4,884 analysts
7
Total ratings
28.57%
Success rate
-33.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sean McCutcheon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Reinstates: Outperform | $9 | $2.78 | +223.74% | 1 | Jul 1, 2025 | |
| BDTX Black Diamond Therapeutics | Reinstates: Outperform | $11 | $2.58 | +326.36% | 1 | Jul 1, 2025 | |
| ENGN enGene Holdings | Initiates: Outperform | $23 | $3.80 | +505.26% | 1 | Nov 27, 2024 | |
| XNCR Xencor | Maintains: Strong Buy | $58 → $40 | $8.42 | +375.06% | 1 | Jun 14, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $92 → $70 | $34.66 | +101.96% | 2 | May 23, 2024 | |
| LEGN Legend Biotech | Initiates: Outperform | $86 | $35.64 | +141.30% | 1 | Mar 13, 2024 |
Compass Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $9
Current: $2.78
Upside: +223.74%
Black Diamond Therapeutics
Jul 1, 2025
Reinstates: Outperform
Price Target: $11
Current: $2.58
Upside: +326.36%
enGene Holdings
Nov 27, 2024
Initiates: Outperform
Price Target: $23
Current: $3.80
Upside: +505.26%
Xencor
Jun 14, 2024
Maintains: Strong Buy
Price Target: $58 → $40
Current: $8.42
Upside: +375.06%
Cytokinetics
May 23, 2024
Maintains: Outperform
Price Target: $92 → $70
Current: $34.66
Upside: +101.96%
Legend Biotech
Mar 13, 2024
Initiates: Outperform
Price Target: $86
Current: $35.64
Upside: +141.30%